A

Amgen

Makes biotech medicines for serious illnesses

Global Demand Insights Senior Associate

Full-TimeUpdated on 10/21/2026
No salary listed
Junior
Bachelor's
Hyderabad, Telangana, India
In Person
Operations & LogisticsSupply Chain Management

About the job

Requirements
  • A bachelor's degree in Business, Economics, Supply Chain, Engineering, Data Science, Statistics, or a related quantitative field is required.
  • At least 2 years of experience in demand planning, forecasting, supply chain analytics, commercial analytics, or related disciplines is required.
  • Proficiency with global demand planning systems such as Anaplan, Kinaxis, SAP, or equivalent is required.
  • Experience working with large datasets and performing quantitative analysis is required.
  • Strong analytical and problem-solving skills are required.
  • The ability to translate analytics into business-relevant narratives for cross-functional stakeholders is required.
  • Strong communication skills are required.
Responsibilities
  • Analyze global, regional, and country-level sales and forecast data across multiple levels of aggregation, including Global Product, Regional Product, and Demand Forecasting Unit.
  • Identify trends, variances, and drivers impacting forecast performance, and provide actionable insights and recommendations to Country Engagement Leads and Commercial partners to inform the monthly consensus forecasting process.
  • Generate recurring and ad hoc analyses to support monthly forecasting and demand review processes.
  • Investigate forecast variances and performance drivers, and provide recommendations to improve forecast quality.
  • Develop and maintain key performance indicator reporting for forecast accuracy, bias, demand performance, and forecast value-add metrics.
  • Monitor forecast performance across multiple levels of aggregation and identify exceptions requiring attention.
  • Support root-cause analysis of forecast deviations and demand changes.
  • Produce exception reports and insights to support country demand reviews, highlighting key areas for discussion and follow-up action.
  • Apply statistical forecasting methods to generate baselines, monitor performance, and assess accuracy across time horizons.
  • Run optimistic and pessimistic scenario analyses to evaluate potential business risks and opportunities, supporting decision-making within the Integrated Business Planning process.
  • Collaborate with Forecast Model Owners and Country Engagement Leads to assess scenario outcomes and recommend actions.
  • Maintain data quality and integrity within global demand planning systems.
  • Partner with system process owners and Information Technology to enhance system capabilities, analytics automation, and visualization.
  • Support integration of advanced analytics and statistical forecasting tools into the end-to-end demand planning process.
  • Identify opportunities to automate reporting, streamline processes, and enhance analytical capabilities.
  • Support implementation of advanced analytics, visualization, and forecasting tools.
  • Contribute to the evolution of demand insight methodologies and best practices.
  • Share knowledge and support capability development across the broader forecasting community.
  • Partner with Global, Regional, and Country Forecasting, Supply Chain, and Commercial teams to align demand insights with business objectives.
  • Provide analytic support and insight generation for global and regional demand review forums.
  • Collaborate with stakeholders across GCF, Integrated Business Planning, and Commercial Operations to evolve forecasting capability and maturity.
Desired Qualifications
  • Knowledge of statistical forecasting principles and demand planning processes.
  • Experience with Power BI, Tableau, or similar data visualization tools.
  • Familiarity with SQL, Python, R, or other analytics tools.
  • Understanding of Integrated Business Planning processes.
  • Experience within the pharmaceutical, biotechnology, or healthcare industry.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.